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Abstract  
Low VWF levels are associated with bleeding symptoms and are a diagnostic criterion 
for von Willebrand disease; the most common inherited bleeding disorder. To date, it is 
unclear which genetic loci are associated with reduced VWF levels. Therefore, we 
conducted a meta-analysis of genome-wide association studies to identify genetic loci 
associated with low VWF levels. For this meta-analysis we included 31,149 participants 
of European ancestry from eleven community-based studies. From all participants VWF 
antigen (VWF:Ag) measurements and genome-wide single nucleotide polymorphisms 
(SNPs) scans were available. Each study conducted analyses using logistic regression of 
SNPs on dichotomized VWF:Ag measures (lowest 5% for blood group O and non-O) 
with an additive genetic model adjusted for age and sex. An inverse-variance weighted 
meta-analysis was performed for VWF:Ag levels.  A total of 97 SNPs exceeded the 
genome-wide significance threshold of 5×10-8 and comprised five loci on four different 
chromosomes: 6q24 (smallest p-value 5.8×10-10), 9q34 (2.4×10-64), 12p13 (5.3×10-22), 
12q23 (1.2×10-8), 13q13 (2.6×10-8). All loci were within or close to genes, including 
STXBP5 (6q24), STAB5 (12q23), ABO (9q34), VWF (12p13), and UFM1 (13q13). Of 
these, UFM1 has not been previously associated with VWF:Ag levels. Four genes that 
were previously associated with VWF levels (VWF, ABO, STXBP5 and STAB2) were 
also associated with low VWF levels, and in addition we identified a new gene, UFM1, 
that is associated with low VWF levels. These findings point to novel mechanisms for 
the occurrence of low VWF levels.  
 
  
 4
Introduction 
Von Willebrand factor (VWF) is a multifunctional glycoprotein, which is secreted by 
endothelial cells and released upon endothelial cell activation. VWF initiates the 
adherence of platelets to the injured vessel wall, and the subsequent platelet aggregation 
facilitates adequate haemostasis1,2.  
Plasma levels of VWF antigen (VWF:Ag) are characterized by a large inter-individual 
variation and range from 0.60 to 1.40 IU/mL in healthy individuals3. Various 
environmental and lifestyle factors affect VWF:Ag levels, but approximately 60% of the 
variability in VWF:Ag levels can be explained by genetic factors4.  
The necessity of maintaining normal VWF levels in the circulation is illustrated by two 
clinical manifestations that may occur when VWF exceeds its normal range. High 
VWF:Ag levels are associated with an increased risk of venous thrombosis and arterial 
thrombosis 5-8. Conversely, low VWF:Ag levels are associated with an increased 
bleeding tendency and are a characteristic of von Willebrand disease (VWD). VWD is 
the most common inherited bleeding disorder in humans and is caused by a quantitative 
deficiency of VWF (type 1 and 3 VWD) and/or a qualitative defect of VWF molecules 
(type 2 VWD) 9.  
Most severe forms of type 1 VWD are caused by dominant-negative family-based 
variations in the VWF gene (VWF) 10,11. However, in individuals with moderately 
decreased VWF:Ag levels VWF variations are often not found and linkage with the 
VWF locus is rarely seen 10,11. Hence, it is difficult to differentiate between subjects 
with physiologically low VWF:Ag levels and subjects with low VWF:Ag levels because 
of VWD12,13. However, since VWF:Ag levels are strongly genetically determined, it is 
expected that more common genetic variations in other genes than VWF are likely to be 
involved in the occurrence of low VWF:Ag levels and therefore in the etiology of type 1 
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VWD. We have previously shown that several loci outside the VWF gene are indeed 
associated with VWF:Ag levels and that the VWF decreasing alleles are more 
frequently observed in individuals diagnosed with VWD 13. To identify common genetic 
loci that are associated with low VWF:Ag levels, related to an increased bleeding 
tendency, we performed a meta-analysis of genome-wide association studies (GWAS) 
in eleven large population-based cohort studies. 
 
Methods 
Study populations 
This meta-analysis was conducted in the CHARGE Consortium14, which includes data 
from several population-based cohort studies. VWF:Ag measurements were available in 
four of these; the Rotterdam Study (RS) I and II , the Framingham Heart Study (FHS), 
and the Atherosclerotic Risk in Communities (ARIC) study. In addition, we included 
data from seven other studies that had VWF:Ag measurements and genome-wide data 
available: the British 1958 Birth cohort (B58C) study, the PROspective Study of 
Pravastatin in the Elderly at Risk (PROSPER), the Prevention of Renal and Vascular 
Endstage Disease (PREVEND) study, Lothian Birth Cohort 1921 and 1936 (LBC1921, 
LBC1936), Vis Croatia Study (CROATIA-Vis) and ORKNEY complex Disease Study 
(ORCADES). The designs of the studies have been described previously15-25.  
Genome-wide scans and VWF:Ag measurements were available for analysis in 31,149 
individuals. Eligible participants were not using a coumarin-based anticoagulant at the 
time of VWF:Ag measurement and were of European ancestry by self-report. All 
studies were approved by their respective institutional review committee. In addition, 
written informed consent was obtained from all participants, as well as permission to 
use their DNA for research purposes.  
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Baseline measurements and von Willebrand factor measures 
Baseline measures of clinical and demographic characteristics were obtained at the time 
of cohort entry for ARIC, CROATIA-Vis, ORCADES, PROSPER, PREVEND and RS, 
and at the time of phenotype measurements for B58C, LBC1921, LBC1936, and FHS. 
Measures were obtained using standardized methods as specified by each study and 
included measures of height and weight, as well as self-reported treatment of diabetes 
and hypertension, current alcohol consumption, and prevalent cardiovascular disease 
(history of myocardial infarction, angina, coronary revascularisation, stroke, or transient 
ischemic attack). Blood group antigen phenotypes (O and non-O) were reconstructed 
using genotype data of rs687289:C>T, which is a marker for the O allele26.  
VWF:Ag was measured in all cohorts using enzyme-linked immunosorbent assays 
(ELISA) (supplementary table 3).   
 
Genotyping 
For the genotyping, DNA was collected from phlebotomy from all studies except B58C, 
which used cell lines. Genome-wide assays of SNPs were conducted independently in 
each cohort using various Affymetrix and Illumina panels (Supplementary table 3). 
Each study conducted genotype quality control and data cleaning, including assessment 
of Hardy-Weinberg equilibrium and variant call rates. Details on genotyping assays 
have been described in detail previously and are provided in supplementary table 314.   
For this analysis we investigated genetic variation in the 22 autosomal chromosomes27. 
Genotypes were coded as 0, 1, and 2 to represent the number of copies of the coded 
alleles for all chromosomes27. Each study independently imputed its genotype data to 
the ≈ 2.6 million SNPs identified in the HapMap Caucasian (CEU) sample from the 
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Centre d’Etude du Polymorphisme Humain28-30. Imputation software, including MACH, 
BIMBAM, or IMPUTE, were used to impute unmeasured genotypes with SNPs that 
passed quality-control criteria based on phased haplotypes observed in HapMap. 
Imputation results were summarized as an “allele dosage”, which was defined as the 
expected number of copies of the minor allele of that SNP (a continuous value between 
0 and 2) for each genotype. Each cohort calculated the ratio of observed to expected 
variance of the dosage statistics for each SNP. This value, which generally ranges from 
0 to 1 (i.e. poor to excellent), reflects imputation quality.  
 
Public Repository: Our data are available on the European Genome-phenome Archive 
(https://ega.crg.eu, accession number EGAS00001001341). 
 
Statistical analysis 
Genotype-phenotype data were analysed independently by each study. VWF:Ag 
measurements were used as dichotomous variable (low versus normal) with low VWF 
defined as the lowest 5% within blood groups, i.e. blood group O and non-O. All studies 
used logistic regression with an additive genetic model adjusted for age and sex to 
conduct analyses of all directly genotyped and imputed SNPs and their association with 
dichotomous VWF:Ag measures. FHS used generalized estimation equations to account 
for familial correlation. ARIC and PROSPER adjusted for field site, additionally. B58C 
adjusted for sex, date and time of sample collection, postal delay, and the nurse who 
performed the inclusion, which also adjusts for the region of residence. Age adjustment 
was not necessary in B58C, since all cohort members were born in one week.   
An inverse-variance weighted meta-analysis was performed using METAL software 
(http://www.sph.umich.edu/csg/abecasis/Metal/index.html) with genomic control 
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correction being applied at the cohort level31.  
The a priori threshold of genome-wide significance was set at a p-value of 5.0 x 10-8. 
When more than one SNP clustered at a locus, the SNP with the smallest p-value was 
selected to represent the locus.  
 
Results 
For this meta-analysis 31,149 participants of European ancestry were included. The 
sample size and participant characteristics from each cohort are displayed in 
supplementary table 1.  The mean age ranged from 45 years in B58C to 87 years in 
LBC1921 and on average 48% of the participants was female. 
A quantile-quantile plot of the observed p-value from meta-analysis against expected p-
value distribution is shown in figure 1. Figure 2 illustrates the primary findings from the 
meta-analysis and presents p-values for each of the interrogated SNPs across the 22 
autosomal chromosomes. A total of 97 SNPs exceeded the genome-wide significance 
threshold of 5 × 10-8 and clustered around five genetic loci on four different 
chromosomes (figure 3). The SNP with the strongest signal was rs8176704:A>G, which 
is located at 9q34 (intron) in the ABO blood group gene (P = 2.4 × 10-64). The odds 
ratio (OR) for having VWF levels in the lowest 5% was 2.83 [95% CI 2.52;3.18]. In 
addition, we performed a conditional analysis. Based on this analysis we found three 
independent signals at 9q34. The analysis shows that rs579459 and rs8176747 are 
independently significant after taking into account the LD structure and their correlation 
with rs817704. The second most significant locus was marked by rs216303:T>C, which 
is located at 12p13 (intron) in the VWF gene (OR 0.57 [95% CI 0.51;0.64], P = 5.3 × 
10-22). The third genome-wide significant signal at chromosomal position 6q24 (intron) 
was within STXBP5 (Syntaxin Binding Protein 5). Rs1221638:A>G was associated with 
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the smallest p-value (5.8 × 10-10) in this region (OR 1.28 [95% CI 1.19;1.39]). The 
fourth statistical significant signal was marked by rs4981022A>G, which is located at 
12q23 (intron) in STAB2 (stabilin-2) (OR 0.79 [95% CI 0.73;0.85], P = 1.2 × 10-8). The 
final genome-wide significant locus was marked by rs17057285:A>C (OR 0.41 [95% 
CI 0.30;0.56], P = 2.6 × 10-8), which is 200kb upstream from UFM1 (ubiquitin-fold 
modifier 1). There are two SNPs close to rs17057285. The first one is rs17057209 
which is 52 kb far from rs17057285 and is in complete LD with rs17057285 (R2 = 1). 
Both of these SNPs are missing in five studies (VIS, ORKNEY, Prevend, LBC1921, 
LBC1936) out of 11 studies who contributed to the study. The third SNP is  rs7323793 
which is 67 kb far and is partly in LD with rs17057285 (R2 = 0.496). Rs7323793 is 
missing only in Prevend Study.  
In addition to our five genome-wide significant loci, five other loci demonstrated 
multiple-SNP hits with p-values below 1.0 × 10-6: rs10848820:A>G (P = 1.2 × 10-7) 
within TSPAN9 (tetraspanin 9), rs4276643:T>C (P = 3.4 × 10-7) within SCARA5 
(scavenger receptor class A, member 5), rs17398299:A>C (P = 4.1 × 10-7) close to 1 
gene, LPHN2 (latrophilin 2), rs5995441:T>C (P = 8.3 × 10-7) within CARD10 (caspase 
recruitment domain family, member 10), and rs3750450:T>G (P = 9.6 × 10-7) within 
EPB41L4B (erythrocyte membrane protein band 4.1 like 4B).  
 
Discussion 
In this meta-analysis of GWA data from eleven population-based cohorts comprising 
31,149 individuals of European ancestry, we identified five genetic loci that are 
associated with low VWF levels: ABO, VWF, STXBP5, STAB2, and UFM1.  
 The most significant signal in our study came from a well-known determinant of 
VWF:Ag levels, the ABO locus. The presence of blood group A and B antigens on 
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VWF molecules leads to a decreased clearance of VWF molecules. Consequently, 
individuals with blood group O have 25% lower VWF plasma concentrations than 
individuals with blood group non-O32. Although we used a different cut-off point for 
low VWF levels for blood group O and non-O separately to minimize the effect of 
blood group, the ABO locus still reached a very high level of statistical significance. 
This implies that blood group O versus non-O explains not the total ABO locus effect, 
and that A or B antigens also determine VWF levels.  Indeed, carriers of the B antigen 
have higher VWF levels than carriers of the A antigen and carriers of both antigens 
have the highest VWF levels33,34.  
The second locus is within the VWF gene. It has been well established that common 
genetic polymorphisms in the VWF gene contribute to the variability in VWF:Ag 
levels35-37. The most significant SNP that marked the VWF locus was rs216303:T>C, 
which is located within an intronic region. Until recently, intronic polymorphisms were 
often considered  less relevant for disease development and regulating protein levels in 
plasma. However, there is now an increasing recognition that intronic variants can 
contribute by for example influencing the form and efficacy of gene splicing and 
mRNA stability37. Another possibility is that SNPs in the intronic regions are in high 
LD with functional SNPs in adjacent regions.  
The third locus is within the STXBP5 gene, which encodes the syntaxin binding protein 
5. STXBP5 can bind to Soluble N-ethylmaleimide-sensitive factor (NSF) Attachment 
protein Receptor (SNARE) proteins, among which syntaxin-2 and syntaxin-4. Syntaxin-
4 has been shown to be involved in Weibel Palade Body exocytosis38, the well known 
mechanism for the secretion of VWF molecules from endothelial cells. We have 
previously shown in a well defined cohort of young patients with a first event of arterial 
thrombosis that genetic variation in STXBP5 is associated with VWF:Ag levels13,39. The 
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LD between rs1221638:A>G and the SNP that had the highest significance in the 
previous meta-analysis is D’ = 0.90 and R2 = 0.67.  
The fourth locus was marked by rs4981022:A>G, which is located in STAB2. Stabilin−2 
is a transmembrane receptor protein and is primarily expressed in liver and spleen 
sinusoidal endothelial cells. Stabilin-2 can bind various ligands, such heparin, LDL, 
bacteria, and advanced glycosylation products, and subjects them to endocytosis40. 
STAB2 variation might be important in the regulation of VWF levels via the clearance 
of VWF molecules.   
The final genome-wide significant locus was marked by rs17057285:A>C, which is 
upstream from UFM1. UFM1 encodes the ubiquitin-fold modifier 1, which has been 
recently identified as a novel protein conjugating system41. Although the precise 
function has not been elucidated yet, the UFM1 cascade seems to be involved in cellular 
homeostasis, influencing cell division, growth and endoplasmatic reticulum function42. 
UFM1 is highly expressed in the pancreatic islets of Langerhans and has a role in the 
development of type-2 diabetes. Another study showed possible involvement in the 
development of ischemic heart disease. In this study chronic inflammation in mice led 
to a strong up regulation of UFM1 in cardiomyocytes43. Since VWF:Ag levels also have 
been associated with an increased risk of ischemic heart disease, this is an interesting 
finding. However, UFM1 has not yet been linked to VWF directly yet and is a novel 
association needing replication.  
Four of the identified loci for low VWF:Ag levels (i.e. ABO, VWF, STXBP5, and 
STAB2) have previously shown to be involved in the regulation of VWF:Ag levels in 
general44. The other identified new genetic loci for continuous VWF:Ag levels (i.e. 
SCARA5, STX2, TC2N, and CLEC4M) were not associated with low VWF levels. 
UFM1 is a novel genetic locus associated with low VWF levels that was not associated 
 12
with the continuous VWF:Ag levels. Rs17057285:A>C, the SNP with the highest P-
value that marks this locus, has a very small minor allele frequency of about 0.5%. 
Therefore this finding should be interpreted with care.  
In today’s clinical practice it is hard to distinguish between physiologically low VWF 
levels and VWF:Ag levels due to VWD, because both VWF levels and bleeding 
symptoms are highly variable and occur frequently in the general population45. Until 
recently, it was believed that low VWF:Ag levels and VWD are caused by variations in 
the VWF gene only. However, now it has been shown that 35% of type 1 (partial 
quantitative deficiency of VWF) VWD patients have no apparent VWF variations10,11. 
This suggests that genetic variations in genes other than VWF may lead to low VWF:Ag 
levels, also in patients diagnosed as having VWD 13. Indeed, our current findings 
confirm this hypothesis that next to ABO blood group and VWF, other genetic loci are 
involved in the occurrence of low VWF levels.  
In the current study we have not included a replication cohort. Generally, it has been 
recommended to include all cohorts in the discovery panel to maximize statistical 
power, rather than use some of the cohorts for replication. In addition, the identified 
genetic loci comprise extremely small p-values and were previously discovered in the 
meta-analysis using VWF:Ag as a continuous measure. For these reasons it is very 
unlikely that our findings are false-positive or came out by chance. 
In conclusion, we identified five genetic loci that are associated with low VWF levels: 
ABO, VWF, STXBP5, STAB2, and UFM1. Our findings confirm the hypothesis that 
genes other than VWF lead to low VWF:Ag levels. Further research is warranted in 
order to elucidate whether these genetic loci also contribute to the incidence of bleeding 
symptoms and VWD.   
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Table 1. Genome-wide Significant Association of 5 Loci with low VWF levels  
SNP 
Most significant  Region MAF P OR [95% CI]† Het I2 Het p-value Gene 
rs8176704 hg18:g.13512373A>G 9q34 0.07 2.4 × 10-64 2.83 [2.52;3.18] 46.4 0.01 ABO (intronic) 
rs216303 hg18:g.6029306T>C 12p13 0.09 5.3 × 10-22 0.57 [0.51;0.64] -12.6 0.39  VWF (intronic) 
rs1221638 hg18:g.147576998A>G 6q24 0.43 5.8 × 10-10 1.28 [1.19;1.39] 0 0.85 STXBP5 (intronic) 
rs4981022 hg18:g.102674004A>G 12q23 0.32 1.2 × 10-08 0.79 [0.73;0.85] -0.5 0.29  STAB2 (intronic) 
rs17057285 hg18:g.37635821A>C 13q13 0.005 2.6 × 10-08 0.42 [0.30;0.56] 23.2 0.10 200 kb from UFM1 
Abbreviations used in this table are: SNP for single nucleotide polymorphism, MAF for minor allele frequency, P for statistical significance 
level, OR for odds ratio, and Het for heterogeneity.  Reference sequence Hg 18 (NCBI build 36) 
†Odds Ratio (OR) represents the risk of having VWF:Ag levels in the lowest 5% relative to the upper 95%.  
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Figure legends 
Figure 1. Quantile-quantile plot of the observed and expected distribution of P values for all 
~2.6 million SNPs and their association with low VWF levels based on meta-analyzed data. 
 
Figure 2. −Log10 P values for each of the ~2.6 million tests performed as part of the GWA 
analysis of low VWF levels. The grey dashed horizontal line marks the 5 × 10-8 P value 
threshold of genome-wide significance. 
 
Figure 3. Regional plots of top marker loci associated with low VWF levels. A through E: 
The association P values (−log10 transformed, indicated by the left y axis) for SNPs in a 60-
kb region of each of the five loci (ABO, VWF, STXBP5, STX2, UFM1) are plotted against 
their chromosome positions (NCBI build 3) on x axis. The top SNPs are presented as a large 
diamond in red font and neighbouring variants are presented in different colors based on 
linkage disequilibrium based on HapMap Caucasian data: red: 1 ≤ r2 > 0.8; orange: 0.8 ≥ r2 > 
0.6; yellow: 0.6 ≥ r2  > 0.3; green: 0.3 ≥ r2  > 0.1; blue: 0.1 ≥ r2  > 0.05; light blue: 0.05 ≥ r2  > 
0.0. The left y-axis is the p-value on the -log10 p-value scale and the gray line marks the 
threshold of genome-wide significance (P = 5 ×10-8). Shown in light blue are the estimated 
recombination rates in HapMap with values indicated by the right y axis. Regional genes and 
their direction of transcription are depicted with green arrows 
